Omeros initiates dosing in phase 1 clinical trial for OMS527 targeting addiction
Omeros announced the first cohort of subjects has been dosed in the Company’s Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 (PDE7) inhibitor in Omeros’ OMS527 program broadly targeting addictions and compulsive disorders. July 17, 2018